scholarly journals Determination of Lipid Profile and Anthropometric Measurements of Multiple Sclerosis Patients: A Controlled Descriptive Study

2019 ◽  
Vol 25 (4) ◽  
pp. 218-228
Author(s):  
Gülşen Delikanlı Akbay ◽  
Erdinç Karakullukçu ◽  
Aslı Akyol Mutlu ◽  
Halit Tanju Besler
2019 ◽  
Vol 25 (4) ◽  
pp. 218-228
Author(s):  
Gülşen Delikanlı Akbay ◽  
Erdinç Karakullukçu ◽  
Aslı Akyol Mutlu ◽  
Halit Tanju Besler

2018 ◽  
Vol 19 (11) ◽  
pp. 3589 ◽  
Author(s):  
Claudia Rossi ◽  
Ilaria Cicalini ◽  
Mirco Zucchelli ◽  
Maria di Ioia ◽  
Marco Onofrj ◽  
...  

Multiple sclerosis (MuS) is an autoimmune disease of the central nervous system characterized by neuroinflammation, neurodegeneration, and degradation of the myelin sheath. Epidemiological studies have shown that the female gender is more susceptible than the male gender to MuS development, with a female-to-male ratio of 2:1. Despite this high onset, women have a better prognosis than men, and the frequency of the relapsing phase decreases during pregnancy, while it increases soon after birth. Therefore, it is interesting to investigate hormonal fluctuations during pregnancy and whether they correlate with metabolic signatures. To gain a deeper inside into the biochemical mechanism of such a multifactorial disease, we adopted targeted metabolomics approaches for the determination of many serum metabolites in 12 pregnant women affected by MuS by mass spectrometry analysis. Our data show a characteristic hormonal fluctuation for estrogens and progesterone, as expected. They also highlight other interesting hormonal alterations for cortisol, corticosterone, 11-deoxycortisol, 4-androstene-3,17-dione, testosterone, and 17α-hydroxyprogesterone. Furthermore, a negative correlation with progesterone levels was observed for amino acids and for acylcarnitines, while an imbalance of different sphingolipids pathways was found during pregnancy. In conclusion, these data are in agreement with the characteristic clinical signs of MuS patients during pregnancy and, if confirmed, they may add an important tessera in the complex mosaic of maternal neuroprotection.


QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Azza AbdelNaser AbdelAziz ◽  
Prof Dr. Rasha Mamdouh Saleh ◽  
Mahmoud Saad Swelam ◽  
Janet Masoud Ayad

Abstract Background Studies have suggested that vitamin D and lipid profile have been linked to the etiology of multiple sclerosis and have an impact on the activity and progression of the disease. Objectives The aim of the present study was to determine correlation between vitamin D level and lipid profile in multiple sclerosis (MS) patients and their effect on disease activity and progression for better management and control of risk factors. Patients and Methods It is a cross-sectional hospital based study carried on clinically definite 111 Relapsing Remitting MS (RRMS) patients according to McDonald criteria 2010 recruited from Multiple sclerosis unit at Ain Shams University Hospitals, both genders included and aged from 18 to 50 years old. All subjects were assessed regarding their basic demographic data, serum vitamin D level and lipid profile and correlated these data with their state of disease activity and degree of disability. Results The mean level of serum vitamin D was 18.93 ± 9.85 ng/mL. Serum vitamin D level was insufficient (< 30 ng/mL) in 81.08% of patients and sufficient (≥ 30 ng/mL) in 18.92% of patients. The mean level of total cholesterol (TC) was 204.9 ± 50.9 mg/dL, of tri-glycerides (TG) was 105.4 ± 44.6 mg/dL, of low density lipoprotein (LDL) was 122.2 ± 38.8 mg/dL and of high density lipoprotein (HDL) level was 56.2 ± 16.6 mg/dL. High relapse frequency was found to be significantly related to low serum vitamin D level with P-value 0.005. Near all lipid related variables were positively correlated to disease duration. TC and TG were positively related to EDSS while HDL was negatively related with it. Number of brain T2 lesions was significantly correlated with TC and TG levels with P-value 0.001 and 0.002 respectively. Fingolimod was found to be associated with dyslipidemia. We found that each 1 ng/mL increase in vitamin D was associated with decrease in TC of 1.48 mg/dL (95% CI: -2.42 to -0.54, P-value 0.002) and increase in HDL of 0.35 mg/dL (95% CI: 0.04 to -0.66, P-value 0.028). Conclusion Vitamin D deficiency is predominant among Egyptian MS patients. Patients with insufficient vitamin D were found to have higher annualized relapse rate (ARR). Patients with dyslipidemia found to have longer duration, more disability and higher brain T2 lesion load. Vitamin D was correlated positively with HDL and negatively with TC.


BMC Neurology ◽  
2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Carolyn E. Schwartz ◽  
Armon Ayandeh ◽  
Murali Ramanathan ◽  
Ralph Benedict ◽  
Michael G. Dwyer ◽  
...  

2009 ◽  
Vol 4 (1) ◽  
pp. 156
Author(s):  
Raquel Sousa Quintanilha ◽  
Luciano Ramos de Lima

ABSTRACTObjective: to evaluaty the quality of live in Multiple Sclerosis patients. Methods: exploratory descriptive study, from quantitative approach, performed with 13 subjects with confirmed clinical diagnosis. The instrument used for data collection was the Functional Assessment of Multiple Sclerosis (FAMS) translated into Portuguese as Escala de Determinação Funcional de Qualidade de Vida em pacientes com Esclerose Múltipla (DEFU). The research project has been approved by the Ethics Committee according protocol number 096/2008. Results: there was a prevalence of women (69.2%) with a mean age of 48.7 years old (SD = 10.45). The aspect which had the highest deficit index was Thinking and Fatigue (M=22.31), followed by Personal Satisfaction (M=16.77), Social and Familiar Status (M=13.08), Mobility (M=12.46), Symptoms (M=11.46) and Emotional State (M=8.31). Emotional State was the aspect with the lowest score for the patients obtained an adequate family support. The reliability of the correlation coefficients among the DEFU sub-scales showed significant results (p


Cytokine ◽  
2017 ◽  
Vol 96 ◽  
pp. 138-143 ◽  
Author(s):  
Mohammad Taheri ◽  
Soudeh Ghafouri-Fard ◽  
Ghasem Solgi ◽  
Arezou Sayad ◽  
Mehrdokht Mazdeh ◽  
...  

2013 ◽  
Vol 20 (5) ◽  
pp. 577-587 ◽  
Author(s):  
H Hegen ◽  
A Millonig ◽  
A Bertolotto ◽  
M Comabella ◽  
G Giovanonni ◽  
...  

Background: Neutralizing antibodies (NAb) affect efficacy of interferon-beta (IFN-b) treatment in multiple sclerosis (MS) patients. NAbs evolve in up to 44% of treated patients, usually between 6–18 months on therapy. Objectives: To investigate whether early binding antibody (BAb) titers or different IFN-b biomarkers predict NAb evolution. Methods: We included patients with MS or clinically isolated syndrome (CIS) receiving de novo IFN-b treatment in this prospective European multicenter study. Blood samples were collected at baseline, before and after the first IFN-b administration, and again after 3, 12 and 24 months on that therapy; for determination of NAbs, BAbs, gene expression of MxA and protein concentrations of MMP-9, TIMP-1, sTRAIL, CXCL-10 and CCL-2. Results: We found that 22 of 164 (13.4%) patients developed NAbs during a median time of 23.8 months on IFN-b treatment. Of these patients, 78.9% were BAb-positive after 3 months. BAb titers ≥ 1:2400 predicted NAb evolution with a sensitivity of 74.7% and a specificity of 98.5%. Cross-sectionally, MxA levels were significantly diminished in the BAb/NAb-positive samples; similarly, CXCL-10 and sTRAIL concentrations in BAb/NAb-positive and BAb-positive/NAb-negative samples, respectively, were also diminished compared to BAb/NAb-negative samples. Conclusions: BAb titers reliably predict NAbs. CXCL-10 is a promising sensitive biomarker for IFN-b response and its abrogation by anti-IFN-b antibodies.


Sign in / Sign up

Export Citation Format

Share Document